Moderna to supply Japan with additional 70 million doses of COVID-19 booster vaccine
On Mar. 16, 2022, Moderna announced an agreement with the Ministry of Health, Labour and Welfare of Japan…
Pfizer and BioNTech submitted for U.S. EUA of additional booster dose of COVID-19 vaccine for older adults
On Mar. 15, 2022, Pfizer and BioNTech announced the companies had submitted an application to the U.S. Food…
COVID-19 | HIV | NIH | Non-Profit Research | Vaccine
NIH launched clinical trial of three mRNA HIV vaccines
On Mar. 14, 2022, researchers from the National Institute of Allergy and Infectious Diseases (NIAID) announced they had…
CDC reported effectiveness of 2-Dose BNT162b2 mRNA vaccine in preventing SARS-CoV-2 infection among children
On Mar. 11, 2022, the BNT162b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine was recommended by CDCﾒs Advisory Committee on Immunization…
Moderna announced first participant dosed in phase 2 study of Omicron-specific bivalent booster candidate
On Mar. 10, 2022, Moderna announced that the first participant had been dosed in the Phase 2 study…
Mandatory masking in schools reduced COVID-19 cases during Delta surge
On Mar. 10, 2022, schools with mandatory masking during the Delta surge had approximately 72% fewer cases of…
IHME reported three times as many deaths worldwide due to COVID-19 than official reports suggested
On Mar. 10, 2022, the Institute for Health Metrics and Evaluation (IHME) reported that more than three times…
City of Hope COVID-19 vaccine showed effectiveness in phase 1 trial
On Mar. 10, 2022, the City of Hope announced that its COVID-19 investigational vaccine licensed to GeoVax Labs…
Pfizer initiated phase 2/3 study of novel COVID-19 oral treatment in pediatric participants
On Mar. 9, 2022, Pfizer announced that it had initiated a Phase 2/3 study, EPIC-PEDS (Evaluation of ProteaseInhibition…
NIH launched trial to study allergic reactions to COVID-19 mRNA vaccine
On Mar. 9, 2022, researchers from the National Institute of Allergy and Infectious Diseases (NIAID) announced a clinical…
Innovation Pharmaceuticals reported additional findings from Brilacidin phase 2 COVID-19 tial results
On Mar. 7, 2022, Innovation Pharma announced the Company was conducting full data analysis of the Phase 2…
CDC reported disparities in COVID-19 vaccination coverage between urban and rural counties
On Mar. 4, 2022, the CDC reported that COVID-19 vaccination coverage with the first dose of the primary…
WHO and MPP welcomed NIHﾒs offer of COVID-19 health technologies to C-TAP
On Mar. 3, 2022, the WHO and the Medicines Patent Pool (MPP) jointly welcomed the announcement that the…
Biotechnology | COVID-19 | FDA | Therapeutics
Sorrento announced FDA authorization to proceed with phase 1 study of Intranasal STI-9199 against Covid-19 viruses
On Mar. 2, 2022, Sorrento Therapeutics announced that it had received clearance from the FDA for its investigational…
CDC reported effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19 among children and adolescents
On Mar. 1, 2022, the CDC reported that Two doses of Pfizer-BioNTech vaccine protect against COVID-19ﾖassociated emergency department…
EMA’s Committee for Medicinal Products for Human Use recommended authorization of Covid-19 vaccine in children (6-11 Years) In the EU
On Feb. 24, 2022, Moderna announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use…
Pfizer and BioNTech received positive CHMP Opinion for COVID-19 vaccine booster in adolescents 12 through 17 years of age in EU
On Feb. 24, 2022, BioNTech announced that the Committee for Medicinal Products for Human Use of the European…
Medicago and GSK announced approval by Health Canada of COVIFENZ, an adjuvanted plant-based COVID-19 vaccine
On Feb. 24, 2022, Medicago and GlaxoSmithKline announced that Health Canada had granted approval for COVIFENZ, COVID-19 vaccine,…
Novavax announced extended durability of protection against infection and disease in UK COVID-19 vaccine phase 3 clinical Trial
On Feb. 24, 2022, Novavax shared extended analysis from its pivotal Phase 3 clinical trial conducted in the…
Sanofi and GSK announced regulatory authorization for COVID-19 vaccine
On Feb. 23, 2022, Sanofi and GSK announced that they planned to submit data from both their booster…
Moderna and Thermo Fisher Scientific announced long-term strategic collaboration
On Feb. 23, 2022, Moderna and Thermo Fisher Scientific announced a 15-year strategic collaboration agreement to enable dedicated…
Novavax announced shipments of COVID-19 vaccine to European Union member states
On Feb. 23, 2022, Novavax announced the first doses of Nuvaxovid COVID-19 Vaccine (recombinant, adjuvanted) had begun shipping…
Published study detailed proof-of-concept for COVID-19 detection via saliva screening
On Feb. 23, 2022, Agilent Technologies announced that researchers at the Indian Institute of Technology Bombay in India…
Biotechnology | COVID-19 | Pharmaceutical | Therapeutics | Vaccine | WHO
Sorrento announced COVISHIELD antibody strongly neutralized BA.2 Omicron sublineage virus
On Feb. 22, 2022, Sorrento Therapeutics announced that additional preclinical results demonstrate broad spectrum COVISHIELD (STI-9167) neutralizing activity…
Moderna expanded global footprint through commercial partnership with Adium in Latin America
On Feb. 22, 2022, Moderna announced a distribution service agreement with Adium Pharma, a leading private Latin American…
Novavax and Serum Institute of India announced first EUA of COVID-19 vaccine in adolescents =12 to <18 in India
On Mar. 22, 2022, Novavax and Serum Institute of India announced that the Drugs Controller General of India…
CDC released the 2022 recommended immunization schedules for children and adolescents, as well as for adults
On Feb. 18, 2022, the U.S. Centers for Disease Control and Prevention (CDC) released the 2022 recommended immunization…
Health Canada authorized Novavax COVID-19 vaccine
On Feb. 17, 2022, Novavax announced that Health Canada had granted authorization for Nuvaxovid COVID-19 Vaccine (Recombinant protein,…
Scientists pinpointed mechanisms associated with severe COVID-19 blood clotting
On Feb. 17, 2022, after studying blood samples from 244 patients hospitalized for COVID-19, a group of researchers,…
Resverlogix expanded phase 2b clinical trial for COVID-19 treatment with first site in Brazil and second in Canada
On Feb. 17, 2022, Resverlogix announced that the first Brazilian site had been initiated for its Phase 2b…